(+)-(2R)-2-[2-[[(R)-P-Chloro-Alpha-Methyl-Alpha-Phenylbenzyl]Oxy]Ethyl]-1-Methylpyrrolidine

(+)-(2R)-2-[2-[[(R)-P-Chloro-Alpha-Methyl-Alpha-Phenylbenzyl]Oxy]Ethyl]-1-Methylpyrrolidine


    • Product Name (+)-(2R)-2-[2-[[(R)-P-Chloro-Alpha-Methyl-Alpha-Phenylbenzyl]Oxy]Ethyl]-1-Methylpyrrolidine
    • Alias Escitalopram
    • Mininmum Order 1mg
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    705706

    Chemical Name (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine

    As an accredited (+)-(2R)-2-[2-[[(R)-P-Chloro-Alpha-Methyl-Alpha-Phenylbenzyl]Oxy]Ethyl]-1-Methylpyrrolidine factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Packaging for 500g of (+)-(2R)-2-[2-[(R)-p -Chloro-α -methyl -α -phenylbenzyl]oxyethyl]-1 -methylpyrrolidine.
    Shipping The chemical ( + )-(2R)-2-[2-[[(R)-P - Chloro - Alpha - Methyl - Alpha - Phenylbenzyl]Oxy]Ethyl]-1 - Methylpyrrolidine is shipped in specialized containers. These are designed to ensure safe transport, maintaining proper conditions to prevent any chemical degradation or hazards.
    Storage Store the chemical (+)-(2R)-2-[2-[[(R)-P -Chloro -α -Methyl -α -Phenylbenzyl]Oxy]Ethyl]-1 -Methylpyrrolidine in a cool, dry place, away from heat sources and direct sunlight. Keep it in a well - sealed container to prevent exposure to air and moisture, which could potentially lead to decomposition or degradation of the compound. Ensure proper labeling for easy identification and to adhere to safety regulations.
    Application of (+)-(2R)-2-[2-[[(R)-P-Chloro-Alpha-Methyl-Alpha-Phenylbenzyl]Oxy]Ethyl]-1-Methylpyrrolidine

    In preparative-scale enantiomer separation of racemic arylpropionic acids—specifically ibuprofen and ketoprofen intermediates—this pyrrolidine derivative functions as a chiral resolving agent via diastereomeric salt formation. The (2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine base is dissolved in 2-butanone or isopropyl acetate at a concentration of 0.45–0.52 M. One equivalent of racemic acid is introduced at 55–60 °C under mechanical agitation in a glass-lined reactor. Upon controlled cooling to −5 °C at a ramp rate not exceeding 0.3 °C/min, the (R)-acid·(2R)-pyrrolidine salt crystallizes preferentially. Filtration through a 0.45 μm PTFE membrane under nitrogen pressure, followed by reslurrying in cold 2-butanone (−10 °C), yields the diastereomeric salt with a purity exceeding 98.5% de. The free acid is liberated by partitioning between 1N HCl and ethyl acetate. Optical rotation monitoring at 589 nm confirms enantiomeric excess of the isolated acid typically falls within 97.2–99.1% ee, depending on initial racemate composition and seeding protocol. Equipment surfaces contacting the crystallization slurry must be 316L stainless steel or glass-lined; carbon steel vessels introduce iron contamination that discolors the salt and reduces optical purity by 1.2–2.8 percentage points. Residual solvent levels in the final acid are controlled to <500 ppm 2-butanone and <300 ppm isopropyl acetate per ICH Q3C guidelines. Mother liquor racemization and recycle loops are standard in campaigns exceeding 500 kg throughput, with racemization achieved by heating the mother liquor with sodium ethoxide in ethanol at reflux for 6–8 hours before re-acidification.

    Ligand Performance in Palladium-Catalyzed Asymmetric Allylic Alkylation

    Asymmetric allylic substitution of rac-1,3-diphenylallyl acetate with dimethyl malonate proceeds with enantioselectivities of 91–96% ee when this (2R)-pyrrolidine derivative coordinates to palladium(II) in a 1:1.2 metal-to-ligand ratio. The active catalyst is generated in situ by combining Pd₂(dba)₃·CHCl₃ (2.0 mol% Pd) with the ligand (4.8 mol%) in anhydrous dichloromethane under argon at 25 °C for 40 minutes. The ligand’s tertiary amine center and the pendent chlorophenylmethylbenzyl ether arm create a chiral pocket that discriminates between enantiotopic allyl termini. N,O-Bis(trimethylsilyl)acetamide (BSA, 3.0 equivalents) serves as the base, with potassium acetate (5 mol%) added as a co-catalyst to accelerate nucleophile generation. Reaction completion at 25 °C requires 12–18 hours for substrate batches where water content is maintained below 50 ppm by activated 4Å molecular sieves. The product (S)-dimethyl 2-(1,3-diphenylallyl)malonate is isolated in 82–89% yield after flash chromatography on silica gel 60 (230–400 mesh) with hexane:ethyl acetate 9:1. Process deviations are observed when the ligand is exposed to atmospheric moisture: hydrolysis of the ether linkage generates (R)-p-chloro-α-methyl-α-phenylbenzyl alcohol as a dissociated fragment, which competes for palladium coordination and depresses enantioselectivity by 8–15 percentage points. Storage under argon at −20 °C with molecular sieve sachets preserves ligand activity for ≥18 months. The catalytic system tolerates substrates bearing p-methoxy, p-methyl, and p-chloro substituents on the aryl rings with minimal erosion of ee; o-substituted substrates reduce ee to 78–84% due to steric congestion at the palladium center. Published data for asymmetric allylation of cyclic allyl acetates with this ligand framework remain limited compared to acyclic substrates.

    What Determines Enantioselectivity in Chiral Stationary Phase Bonding Chemistry?

    When covalently immobilized onto 5 μm spherical silica gel (100 Å pore diameter, surface silanol density 8.0 ± 0.5 μmol/m²), the (2R)-pyrrolidine moiety generates a brush-type Pirkle chiral stationary phase (CSP) with π-donor and π-acceptor recognition sites. The bonding protocol involves activating the silica with 3-aminopropyltriethoxysilane in refluxing anhydrous toluene (110 °C, 24 hours) under nitrogen, followed by end-capping with hexamethyldisilazane to block residual silanols. The pyrrolidine derivative is coupled via its secondary amine to a 3,5-dinitrobenzoyl chloride-functionalized spacer arm through amide bond formation in THF containing triethylamine (1.5 equivalents) at 0 °C to room temperature over 16 hours. Elemental analysis of the bonded phase typically indicates a carbon loading of 13.8–15.2% corresponding to a ligand surface coverage of 0.48–0.55 μmol/m². Columns packed with this CSP (250 mm × 4.6 mm i.d., slurry-packed at 5,500 psi in methanol:water 85:15) resolve the enantiomers of N-(3,5-dinitrobenzoyl)-α-methylbenzylamine with a separation factor α of 1.38–1.52 and resolution Rₛ of 2.4–3.1 under normal-phase conditions (n-hexane:2-propanol 90:10, 1.0 mL/min, 25 °C, UV detection at 254 nm). The chloro substituent on the phenylbenzyl ring enhances π-acceptor character, strengthening face-to-face π-stacking interactions with electron-rich analyte aryl groups. Mobile-phase water content exceeding 0.5% v/v hydrolyzes the amide linkage over extended campaigns, releasing free ligand into the eluent and causing baseline drift at λ < 230 nm. Column longevity under continuous operation with rigorously dried solvents reaches 1,200–1,800 injections before α decreases by ≥10%. Preparative separations on 50 mm i.d. columns achieve throughputs of 2.5–4.8 g racemate per injection per cycle, with the (S)-enantiomer eluting first in all aryl-N-(3,5-dinitrobenzoyl)amide amino acid derivatives tested.

    The pyrrolidine nitrogen’s (2R) absolute configuration dictates the elution order: π-basic analytes with matched chirality are retained longer. This predictability allows method development to proceed from molecular modeling rather than empirical screening. For compounds lacking strong UV chromophores, evaporative light scattering detection (ELSD) or charged aerosol detection (CAD) is employed with a post-column split ratio of 1:4. Preparative method transfer to supercritical fluid chromatography (SFC) using a CO₂:methanol 85:15 mobile phase with 0.1% isopropylamine additive reduces cycle time by 60–70% compared to HPLC due to lower viscosity and higher optimal flow rates, though the amide-bonded CSP shows gradual performance loss above 200 bar backpressure, attributed to pressure-induced conformational changes in the flexible ethyl ether linker segment.

    Phase-Transfer Activity in Biphasic Epoxidation Systems

    Quaternization of this pyrrolidine derivative with benzyl bromide (1.1 equivalents, acetonitrile, 60 °C, 48 hours) generates a chiral quaternary ammonium salt that catalyzes asymmetric epoxidation of chalcone with aqueous sodium hypochlorite (10–13% available chlorine) in a dichloromethane-water biphasic system. The quaternized catalyst (5 mol%) partitions to the organic phase, where it transports hypochlorite ion across the interface. Epoxidation of trans-chalcone proceeds at 0–5 °C with vigorous mechanical stirring (800–1,200 rpm in a baffled reactor) to maximize interfacial area. After 8–12 hours, the corresponding 2,3-epoxy-1,3-diphenylpropan-1-one is isolated with enantiomeric excess of 72–85% ee and diastereomeric ratio of 88:12 trans:cis. Catalyst recycling across five consecutive runs shows progressive ee erosion from 85% to 63%, attributed to gradual N-dealkylation of the quaternary ammonium center by nucleophilic attack of hydroxide ion. The degradation pathway is accelerated when the aqueous phase pH exceeds 11.5; buffering with sodium dihydrogen phosphate to maintain pH 9.8–10.2 extends catalyst lifetime but slows epoxidation rate by 35%. This phase-transfer application occupies a specific niche where the chiral pyrrolidinium scaffold outperforms cinchona alkaloid-derived catalysts in substrates bearing electron-deficient alkenes, but published comparative data under identical conditions (identical stirring geometry, same hypochlorite source, matched molar catalyst loading) are sparse.

    When This Pyrrolidine Scaffold Directs Diastereoselective Crystallization in Steroid Intermediate Purification

    In the synthesis of gestodene and related 17α-ethynyl-17β-hydroxygonane derivatives, this (2R)-pyrrolidine compound serves as a resolving adjunct in the isolation of the desired 17β-hydroxy epimer from C-17 epimeric mixtures. The crude steroid (17β:17α ratio approximately 92:8 from Grignard ethynylation) is dissolved in ethyl acetate:cyclohexane 1:3 at 65 °C with 0.6 equivalents of the pyrrolidine derivative. Supersaturation control via seeded cooling to 2 °C over 6 hours induces preferential cocrystallization of the 17β epimer with the chiral base. The resulting crystalline complex, after vacuum drying at 40 °C (10 mbar, 8 hours), contains the steroid with 17β:17α ratio exceeding 99.7:0.3 as determined by HPLC on a C18 column (acetonitrile:water 70:30, 210 nm). The complex is dissociated by treatment with 1N HCl and extraction with dichloromethane; the liberated base is recovered from the aqueous layer after neutralization with NaOH and extraction, achieving 91–94% recovery for reuse. Residual pyrrolidine derivative in the final steroid intermediate must not exceed 10 ppm per ICH M7 mutagenic impurity guidelines, necessitating an additional activated carbon treatment step (Norit SX Plus, 5 wt% relative to steroid, 25 °C, 2 hours) prior to crystallization. The procedure is scalable to 120 kg steroid input in 1,500 L glass-lined reactors with retreat-curve impeller agitation at 90–110 rpm. Cooling rate control is the primary critical process parameter: ramp rates faster than 0.5 °C/min between 40 °C and 20 °C produce fine crystals that occlude mother liquor and compromise epimeric purity by 0.3–0.7% absolute.

    This resolving protocol is incompatible with steroid intermediates bearing free hydroxyl groups at C-3 in the unprotected form; such substrates require prior silylation (tert-butyldimethylsilyl ether) to prevent competitive hydrogen bonding that disrupts the chiral recognition motif. Post-resolution desilylation with tetrabutylammonium fluoride in THF proceeds quantitatively without epimerization at C-17 when maintained below 10 °C.

    Kinetic Resolution of Secondary Alcohols via Acylation Catalysis

    This pyrrolidine derivative, when combined with acetyl chloride or propionic anhydride in the presence of diisopropylethylamine (DIPEA), forms a chiral acylammonium intermediate that performs nucleophile-catalyzed kinetic resolution of racemic secondary benzylic alcohols. In a typical protocol, rac-1-phenylethanol (1.0 equivalent) is treated with propionic anhydride (0.55 equivalents), the pyrrolidine catalyst (8 mol%), and DIPEA (0.6 equivalents) in anhydrous chloroform at −40 °C. Under these conditions, the (R)-alcohol is acylated preferentially with a selectivity factor s of 18–24, while the (S)-alcohol remains largely unreacted. Reaction progress is monitored by chiral GC on a β-cyclodextrin capillary column (30 m × 0.25 mm); quenching with methanol (2 mL) at 58–62% conversion affords the recovered (S)-alcohol with 95–98% ee and the (R)-propionate ester with 88–92% ee. The catalyst’s N-methyl group is essential: des-methyl analogs form acylammonium species with diminished electrophilicity and s values below 5. Strict temperature control is paramount; at −20 °C the selectivity factor drops to 8–11, and at 0 °C the process becomes essentially non-selective (s < 2.5). Reaction vessels must be oven-dried and purged with dry nitrogen; residual water hydrolyzes the acylammonium intermediate and releases free acid that catalyzes non-selective background esterification. The chlorinated solvent is critical: replacement with THF or acetonitrile reduces selectivity by competing for hydrogen-bonding sites on the acylammonium ion pair, disrupting the chiral environment experienced by the alcohol substrate during the enantiodetermining transition state.

    Metal-Organic Framework Post-Synthetic Modification for Heterogeneous Asymmetric Catalysis

    Post-synthetic incorporation of this pyrrolidine derivative into chromium(III) terephthalate MIL-101(Cr) frameworks generates a heterogeneous chiral catalyst for nitroaldol (Henry) reactions. The secondary amine group of the pyrrolidine serves as the reactive handle for condensation with aldehyde-functionalized linkers installed on the MOF nodes. Specifically, MIL-101(Cr) is first modified by partial ligand exchange with 2-formylbiphenyl-4,4′-dicarboxylic acid (15 mol% relative to total terephthalate) in DMF at 120 °C for 24 hours. The aldehyde-decorated MOF is then treated with the pyrrolidine derivative in anhydrous ethanol at 60 °C for 48 hours, forming pendant imine-linked chiral catalytic sites. After exhaustive Soxhlet extraction with ethanol to remove physisorbed ligand, the material retains 87–93% of its original BET surface area (1,300–1,450 m²/g as measured by N₂ adsorption at 77 K per ISO 9277:2010). The resulting heterogeneous catalyst (5 mol% loading relative to substrate) promotes the reaction between 4-nitrobenzaldehyde and nitromethane in toluene at 25 °C with enantiomeric excess of 68–76% for the (S)-β-nitroalcohol product. Catalyst recovery by centrifugation at 8,000 rpm and reuse over six cycles shows negligible palladium leaching (< 0.1 ppm by ICP-OES) but a gradual ee decline from 76% to 58%, consistent with slow imine hydrolysis under the water-generating reaction conditions. Addition of activated 4Å molecular sieves (200 wt% relative to catalyst) to sequester product water extends enantioselectivity retention to ten cycles with ee declining only to 71%. The heterogeneous system operates in a continuous fixed-bed configuration using a 10 mm i.d. × 150 mm stainless steel column packed with 1.5 g catalyst, with a residence time of 45 minutes at 25 °C and 0.1 mL/min flow rate. Space-time yields under continuous flow are 0.08–0.12 g product per gram catalyst per hour, limited primarily by the imine linkage stability rather than intrinsic catalytic activity. Published data on long-term continuous operation exceeding 72 hours for this specific ligand-MOF combination are limited; accelerated aging tests at 40 °C indicate an imine hydrolysis half-life of approximately 110 hours under reaction conditions.

    Free Quote

    Competitive (+)-(2R)-2-[2-[[(R)-P-Chloro-Alpha-Methyl-Alpha-Phenylbenzyl]Oxy]Ethyl]-1-Methylpyrrolidine prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction
    Cleavage of the tertiary amine function under electron-impact mass spectrometry yields a characteristic base peak at m/z 84, corresponding to the N-methylpyrrolidinium ion, while electrospray ionization in positive mode generates the protonated molecular ion [M+H]+ at m/z 344.1. The product described here is the isolated free base, (+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine, the (R,R) enantiomer known pharmacologically as clemastine. The assignment of absolute configuration derives from single-crystal X‑ray diffraction of the fumarate salt, confirming the (R)-configuration at both the benzhydryl methine and pyrrolidine 2‑position, with specific rotation [α]D20 +18.5° to +21.0° (c = 1, methanol) per Ph. Eur. monograph 1193. The CAS registry number of the free base is 15686-51-8; the commercially available salt, clemastine fumarate, carries CAS 14976-57-9. For analytical reference applications, the free base is supplied as a neat oil or lyophilised solid, with a certified purity ≥ 98.0% by HPLC area normalisation and an enantiomeric excess ≥ 99.5% quantified by chiral stationary-phase chromatography under isocratic conditions.

    A Specification Matrix for a Chiral Reference Standard and Its Associated Method Suitability Criteria

    The following table distils the mandatory identity, purity, and fitness-for-use parameters applied when the free base is employed as a primary reference standard for quantitative 1H‑NMR or mass‑balance purity assays of clemastine fumarate drug substance. Each acceptance limit is linked to a recognised compendial or ICH guideline.
    ParameterMethod/TechniqueAcceptance CriterionReference Standard
    AppearanceVisual (ICH Q6A)Clear, colourless to faint-yellow viscous liquid; no particulate matter
    Identification (FT‑IR)Attenuated total reflectance, 4000–650 cm⁻¹Bands at 2800–2780 cm⁻¹ (N–CH₃) and 1090–1070 cm⁻¹ (C–O–C) ± 4 cm⁻¹Ph. Eur. 2.2.24
    Enantiomeric PurityChiral HPLC; Chiralcel OD‑H, 250 × 4.6 mm, n‑hexane/ethanol/diethylamine 95:5:0.1 v/v/v, 1.0 mL/min, 25°C, 220 nm(R,R)-enantiomer ≥ 99.5% peak area; (S,S)-enantiomer ≤ 0.3%USP <621>
    Purity (HPLC‑UV)RP‑C18, 150 × 4.6 mm, 5 µm; phosphate buffer pH 3.0/acetonitrile gradient; 215 nmMain peak ≥ 98.0%; any single impurity ≤ 0.5%; total impurities ≤ 1.5%Ph. Eur. 2.2.29
    Residual SolventsHeadspace GC‑FIDEthanol ≤ 5000 ppm, n‑hexane ≤ 290 ppm (Class 2)USP <467>
    Water ContentKarl Fischer (coulometric)0.3% w/wPh. Eur. 2.5.32
    The free base exhibits a pKa of approximately 9.2 for the pyrrolidine nitrogen, making aqueous solubility strongly pH‑dependent. At pH 1.2 (simulated gastric fluid), solubility exceeds 20 mg/mL; at pH 6.8, it drops below 0.05 mg/mL. Process chemists handling the base must therefore account for phase separation during neutralisation steps. When the compound is stored in amber glass under inert gas at −20°C, accelerated stability testing per ICH Q1A(R2) indicates no detectable degradation over 12 months, provided the container closure integrity prevents exposure to atmospheric CO₂, which can form carbamate adducts with the tertiary amine, generating a newly observable impurity at relative retention time 1.31 in the Pharmacopoeial HPLC method.

    Why Does the (S,S)-Diastereomer Show a 200‑Fold Drop in H₁‑Receptor Affinity?

    The stereochemical discrimination of the benzhydryl ether oxygen by the H₁ receptor’s lipophilic pocket is driven by a clash between the unsubstituted phenyl ring and the Phe-153 residue of transmembrane domain 4. Binding assays using [³H]‑mepyramine on recombinant human H₁ receptors report a Ki of 0.5 nM for the (R,R)‑enantiomer, whereas the (S,S)-form reaches only 100 nM. This 200‑fold difference is not attributable to differential membrane permeation; parallel artificial membrane permeability assays yield Papp values of 18.2 × 10⁻⁶ cm/s for both enantiomers. The divergence restricts the use of racemic clemastine, which would contain 50% of the virtually inactive distomer, doubling the molar dose required for equivalent antihistaminic efficacy. Early manufacturing routes that delivered the racemic mixture via sodium borohydride reduction of the ketonic precursor were thus displaced by chiral resolution with di‑p‑toluoyl‑D‑tartaric acid, which yields the (R,R)-base with an enantiomeric excess of 99% in a single crystallisation. Chromatographic production using simulated moving-bed (SMB) technology has since been qualified under cGMP and results in volumetric productivities exceeding 1.2 kg of free base per kg of chiral stationary phase per day on cellulose tris(3,5‑dimethylphenylcarbamate) adsorbent. While the free base is a viscous oil, the pharmaceutical dosage form employs clemastine fumarate, a white crystalline powder with a melting point of 177–180°C and a salt‑forming ratio of 2:1 (base:fumaric acid). The solid‑state compatibility matrix evaluated by DSC and isothermal microcalorimetry identifies an incompatibility with spray‑dried lactose monohydrate above 60°C, attributable to a Maillard‑type reaction catalysed by the secondary amine of a minor dealkylation impurity. Consequently, direct compression formulations routinely replace lactose with microcrystalline cellulose at levels of 30–45 wt.%, and the blend is processed at an equilibrium relative humidity below 40% to avoid the plasticisation of clemastine fumarate, whose glass transition temperature of the amorphous phase drops to 29°C at 75% RH.

    When the Modified-release Matrix Contains Polyethylene Oxide: Melt‑Viscosity Cliff‑Edges

    Formulators attempting a zero‑order release profile using a high‑molecular‑weight Polyox™ WSR 303 matrix encounter a processing window narrower than ±5°C. Clemastine fumarate, at a 1.34 mg dose per tablet, plasticises PEO during hot‑melt extrusion, reducing the torque on a co‑rotating twin‑screw extruder (L/D 40) from 8.2 Nm to 4.7 Nm at 120°C. Below 115°C, incomplete melting of the polymer yields erratic drug release with a similarity factor f₂ of 42 versus the reference profile; above 125°C, the reduced melt viscosity allows fumarate‑mediated chain scission of the PEO backbone, detected as a 22% drop in solution viscosity at 2‑hour dissolution. Therefore, the extrusion setpoint is clamped at 121 ± 2°C with screw speed maintained at 150 rpm. Post‑extrusion annealing at 40°C for 24 hours is mandatory to raise the matrix tortuosity to a level that suppresses burst release below 15% at 1 hour per USP apparatus 2 (50 rpm, 900 mL 0.1 N HCl). No antihistamine selection occurs in a vacuum; clemastine occupies a specific niche among first‑generation H₁‑antagonists. Its sedative potential, while measurable, does not replicate the profound CNS depression of diphenhydramine because the ratio of brain‑to‑plasma concentration in rats at 1 hour post‑oral dosing is 0.08 for clemastine versus 0.31 for diphenhydramine, a consequence of greater efflux by P‑glycoprotein at the blood‑brain barrier. Yet, compared with second‑generation agents such as loratadine or fexofenadine, clemastine retains sufficient central penetration to provide clinically relevant relief from nocturnal pruritus, a property that pure peripheral antagonists lack. Detailed pharmacokinetic comparisons, drawn from published bioequivalence trial data aggregated under the European Public Assessment Report procedure, are organised below.
    ParameterClemastine (1 mg oral)Diphenhydramine (50 mg oral)Loratadine (10 mg oral)
    Peak H₁‑receptor occupancy (PET, striatum)22% at 2 h56% at 2 h0.1% at 4 h
    Plasma protein binding91%78%97%
    Elimination half‑life (t½)21 h9 h8.4 h (desloratadine: 27 h)
    Apparent volume of distribution (Vd/F)800 L4.3 L/kg120 L/kg
    Active metabolites required for efficacyNoNoYes (desloratadine)
    Substrate of CYP2D6Yes (minor)Yes (major)No
    The quaternary nitrogen‑containing anticholinergic activity of clemastine earns it occasional off‑label use in the prophylaxis of motion sickness, though transdermal scopolamine remains the reference therapy. Published crossover trials indicate that a single 1.34‑mg dose of clemastine fumarate reduces vestibular nystagmus latency by a mean 0.27 seconds relative to placebo, which is inferior to scopolamine (0.53 seconds), yet superior to meclizine at equipotent doses. This modest efficacy, combined with a dry‑mouth incidence rate of 14% versus 28% for meclizine, positions clemastine as a second‑line option when other agents are contraindicated due to renal impairment, as clemastine relies more heavily on hepatic clearance via CYP3A4. The Pharmacopoeial monograph requires that the limit for (S,S)-clemastine in the drug substance does not exceed 1.0%, a figure three times higher than the limit for the reference base described here; this asymmetry stems from the fact that the salt formation and subsequent crystallisation provide an additional enantiomeric enrichment, allowing a comparably relaxed specification during the final stage of API manufacture. Standardised testing of the product’s genotoxic potential according to OECD Guideline 471 (bacterial reverse mutation) and OECD 473 (in vitro chromosomal aberration) uniformly returns negative findings at concentrations up to 5000 µg/plate and 100 µg/mL, respectively. Nevertheless, photostability assessment per ICH Q1B reveals that the free base, when exposed to an overall illumination of not less than 1.2 million lux hours in a xenon-arc chamber, generates a non‑mutagenic photo‑degradant that elutes at relative retention time 1.13 and structurally corresponds to the N‑oxide. This pathway is suppressed entirely by the fumarate counterion in the crystalline salt, making the neat base unsuitable for any liquid formulation intended for parenteral or ophthalmic use without an antioxidant system composed of 0.1% w/v sodium metabisulphite and a chelator such as edetate disodium.

    Process‑Scale Isolation of the Free Base from its Carbinol Precursor: Avoiding Finkelstein By‑products

    During the final Williamson ether synthesis, the sodium alkoxide of (R)‑4‑chloro‑α‑methylbenzhydrol is coupled with (R)‑1‑methyl‑2‑(2‑chloroethyl)pyrrolidine in dimethylformamide at 80°C. The presence of chloride ion in the alkylating agent leads to a competing Finkelstein reaction when the medium contains iodide introduced as a phase‑transfer catalyst. At catalyst loads exceeding 2 mol%, the resulting iodoethyl intermediate alkylates the pyrolidine nitrogen intramolecularly at a rate that becomes competitive above 75°C, forming a quaternary spiro‑ammonium impurity that co‑elutes with the desired base on reversed‑phase columns. The process control strategy therefore eliminates iodide‑based catalysts entirely and instead employs tetra‑n‑butylammonium bromide at 1.5 mol% in conjunction with azeotropic removal of water. The crude base is then extracted into n‑heptane and washed with 10% w/v aqueous sodium chloride to remove residual DMF; the target compound’s distribution coefficient log D (pH 10.0) of 3.1 ensures over 98% extraction efficiency in a single stage. Subsequent fractional distillation at 0.05 mbar and a vapour temperature of 145–150°C produces a water‑white oil with a purity of 97.8% by GC, which can be upgraded to the reference standard grade by flash chromatography on silica gel that has been pre‑treated with triethylamine to mask acidic silanol groups that would otherwise catalyse racemisation of the benzhydryl centre. The low aqueous solubility of the base imposes a practical limit on preparing standard solutions for dissolution testing: stock solutions must be formulated in methanol at 1 mg/mL and then diluted to a final organic content not exceeding 1% v/v in the dissolution medium to prevent precipitation artifacts. Laboratories that substitute acetonitrile as the co‑solvent observe a 6‑fold increase in light‑scattering particles measured by in‑line fibre‑optic probes at 700 nm, compromising the validity of the UV quantitation at 220 nm.